Gain Contingency, Number of Defendants

No definition available.

Name:	pfe_GainContingencyNumberofDefendants
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Site Contingency, Regulatory Proceedings, Disclosure Threshold

+ References

No definition available.

+ Details

Name:	pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found not to have infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=pfe_MektoviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerAndVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pfe_ExpirationPeriodAxis=pfe_Expiring2030Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pfe_ExpirationPeriodAxis=pfe_Expiring2033Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions	1 Months Ended			12 Months Ended
	Sep. 30, 2022 patent	Aug. 31, 2022 patent	Jul. 31, 2022 patent	Dec. 31, 2017 patent defendant	Oct. 02, 2022 USD ($)
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws \| $					$ 1
Mektovi [Member] \| Pfizer and Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon		6
Mektovi [Member] \| Pfizer and Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2030 [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon		2
Mektovi [Member] \| Pfizer and Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2033 [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon		2
Comirnaty direct sales and alliance revenues [Member] \| ModernaTX Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon	2
Comirnaty direct sales and alliance revenues [Member] \| Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents found not infringed			3
Eliquis alliance revenues and direct sales [Member] \| Pfizer and BMS Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon				3
Number of defendants \| defendant				25
Number of patents allegedly infringed upon, expired December 2019				1